glp-1 news today 2025 november 6 ISPOR 2025: Exploring reasons for discontinuation Weight-loss drug makers announce pricing

These two peptides (GLP-1 and GIP) potentiate glucose-stimulated insulin secretion in an additive manner, likely contribute equally to the incretin effect and together can fully account for the majority of the incretin effect in humans

What we can do in this space as a supplement industry is we can turn around and we can identify three different roles: First, we can prevent gaps that may arise, whether you reduce your intake because youre less hungry, youre changing your food choices or your digestion is being altered by the medication

Mol Endocrinol 16: 21352144, 2002

185,186,187,188 In the future, GLP-1R agonists may benefit all patients with metabolic cardiovascular risk by slowing the progression of cardiac remodeling, thereby reducing cardiovascular risk

Lipid effects were generally neutral

Safety and tolerability in older age groups, polypharmacy, kidney, and hepatic impairment